Shalby Ltd
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, renal transplantations, etc.[1]
The company is the global leader in knee replacement surgery and one of the top Indian hospitals in joint replacement surgery.
- Market Cap ₹ 1,724 Cr.
- Current Price ₹ 160
- High / Low ₹ 275 / 126
- Stock P/E 23.2
- Book Value ₹ 109
- Dividend Yield 0.00 %
- ROCE 11.6 %
- ROE 7.19 %
- Face Value ₹ 10.0
Pros
Cons
- Company has a low return on equity of 8.43% over last 3 years.
- Dividend payout has been low at 9.45% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare BSE Allcap BSE 1000
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2011 | Mar 2014 | Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 132 | 241 | 263 | 322 | 380 | 462 | 484 | 419 | 647 | 708 | 830 | 873 | 883 | |
| 107 | 177 | 192 | 250 | 300 | 379 | 401 | 331 | 516 | 565 | 651 | 712 | 737 | |
| Operating Profit | 25 | 64 | 70 | 73 | 80 | 84 | 83 | 88 | 131 | 143 | 179 | 161 | 146 |
| OPM % | 19% | 27% | 27% | 23% | 21% | 18% | 17% | 21% | 20% | 20% | 22% | 18% | 17% |
| 1 | 3 | 2 | 6 | 10 | 9 | 18 | 9 | 9 | 20 | 21 | 26 | 24 | |
| Interest | 0 | 2 | 5 | 11 | 12 | 9 | 7 | 4 | 4 | 4 | 4 | 13 | 13 |
| Depreciation | 5 | 10 | 20 | 16 | 22 | 33 | 36 | 37 | 36 | 37 | 37 | 39 | 39 |
| Profit before tax | 21 | 56 | 47 | 52 | 55 | 51 | 57 | 55 | 100 | 121 | 158 | 136 | 118 |
| Tax % | 34% | 26% | 39% | 42% | 26% | 37% | 51% | 23% | 30% | 33% | 34% | 38% | |
| 14 | 41 | 28 | 30 | 40 | 32 | 28 | 43 | 70 | 81 | 104 | 84 | 74 | |
| EPS in Rs | 5.47 | 11.79 | 8.15 | 3.47 | 3.75 | 2.97 | 2.59 | 3.97 | 6.46 | 7.48 | 9.61 | 7.76 | 6.88 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 17% | 19% | 25% | 15% | 16% | 12% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 13% |
| 3 Years: | 11% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 23% |
| 3 Years: | 3% |
| TTM: | -19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 3% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 8% |
| Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2011 | Mar 2014 | Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 35 | 35 | 87 | 108 | 108 | 108 | 108 | 108 | 107 | 107 | 107 | 108 |
| Reserves | 23 | 111 | 137 | 171 | 657 | 686 | 706 | 742 | 799 | 863 | 955 | 1,027 | 1,072 |
| 0 | 37 | 98 | 325 | 114 | 71 | 62 | 44 | 41 | 34 | 121 | 110 | 135 | |
| 19 | 32 | 77 | 99 | 96 | 91 | 105 | 119 | 139 | 163 | 192 | 226 | 241 | |
| Total Liabilities | 67 | 215 | 347 | 682 | 975 | 956 | 981 | 1,012 | 1,087 | 1,167 | 1,376 | 1,470 | 1,556 |
| 31 | 105 | 144 | 312 | 647 | 689 | 670 | 658 | 628 | 603 | 599 | 579 | 566 | |
| CWIP | 0 | 5 | 91 | 221 | 47 | 3 | 6 | 8 | 6 | 10 | 5 | 8 | 53 |
| Investments | 6 | 19 | 26 | 10 | 10 | 24 | 43 | 32 | 62 | 313 | 511 | 599 | 588 |
| 30 | 86 | 86 | 139 | 270 | 239 | 262 | 315 | 391 | 242 | 260 | 284 | 349 | |
| Total Assets | 67 | 215 | 347 | 682 | 975 | 956 | 981 | 1,012 | 1,087 | 1,167 | 1,376 | 1,470 | 1,556 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2011 | Mar 2014 | Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 71 | 15 | 46 | 57 | 77 | 101 | 165 | 140 | 149 | |||
| -5 | -157 | -241 | -0 | -32 | -52 | -40 | -172 | -206 | -101 | |||
| -3 | 89 | 226 | -51 | -22 | -28 | -17 | -38 | 72 | -36 | |||
| Net Cash Flow | -1 | 3 | -1 | -6 | 3 | -2 | 43 | -46 | 6 | 12 | ||
| Free Cash Flow | 2 | -87 | -123 | 14 | 37 | 56 | 93 | 162 | 110 | 126 | ||
| CFO/OP | 56% | 113% | 34% | 67% | 93% | 98% | 94% | 134% | 89% | 99% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2011 | Mar 2014 | Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 25 | 21 | 28 | 38 | 48 | 64 | 69 | 81 | 53 | 46 | 52 | 55 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 25 | 21 | 28 | 38 | 48 | 64 | 69 | 81 | 53 | 46 | 52 | 55 |
| Working Capital Days | 16 | 29 | -83 | -54 | -15 | 61 | 73 | 80 | 73 | 35 | 38 | 37 |
| ROCE % | 48% | 23% | 9% | 7% | 7% | 7% | 12% | 13% | 14% | 12% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bed Capacity Numbers |
|
|||||||||||
| ALOS Days |
||||||||||||
| ARPOB ₹ / Day |
||||||||||||
| Operational Beds Numbers |
||||||||||||
| Occupied Beds Numbers |
||||||||||||
| Total Surgery Count Numbers |
||||||||||||
| Shalby Academy Students Enrolled Numbers |
||||||||||||
| Orthopedic Implant Components Sold Numbers |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
1d - Shalby confirms non-applicability of Large Corporate criteria for FY ended March 31, 2026.
-
Intimation Of Receipt Of Approval For Kidney Transplant At Shalby Hospitals, Krishna Unit-Regulation 30 Of SEBI (LODR) Regulations, 2015
11 Apr - Shalby Krishna unit, Ahmedabad received 5-year kidney transplant approval effective April 9, 2026.
-
Update On Pending Litigation - Order Passed By Statutory Authority (Disclosure Under Reg. 30 Of SEBI (LODR))
11 Apr - ITAT Ahmedabad disallowed appeal and raised Rs. 4.14 crore demand on March 16, 2026.
-
Giving Guarantees/Indemnity/ Becoming A Surety For Third Party
9 Apr - Shalby issued an SBLC up to USD 13.27 million for step-down subsidiary SAT Inc.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
3 Apr - Submitted Regulation 74(5) demat/remat certificate for quarter ended March 31, 2026.
Annual reports
Concalls
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Jul 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Dec 2021Transcript PPT
-
Oct 2021TranscriptAI SummaryPPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
May 2021Transcript PPT
-
May 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
Jan 2021Transcript PPT
-
Jan 2021TranscriptAI SummaryPPT
-
Oct 2020TranscriptPPT
-
Oct 2020Transcript PPT
-
Sep 2020TranscriptAI SummaryPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptAI SummaryPPT
-
Mar 2018TranscriptAI SummaryPPT
Business Segments
1) Healthcare Services (90% in H1 FY25 vs 96% in FY22): [1] [2] The company manages a network of 11 multispecialty tertiary hospitals and 5 orthopedic centers spanning 13 cities across India, with a total capacity of over 2,350 hospital beds, it provides services across 30+ specialties. Additionally, it operates 60 outpatient clinics domestically and 23 internationally. Between FY22 and FY24, segment revenue increased by 28%, driven by growth in in-patient numbers, including daycare services, and overall surgery count. [3] [4]